The creation of nanoscale computers for use in precision health care has long been a dream of many scientists and health care providers. Now, the research paves the way for the construction of complex nanoscale computers for the prevention and treatment of cancer and other diseases.

People at risk from strokes and heart attacks could benefit from personalised clotting profiles to help clinicians prescribe more precise treatments, thanks to new research.

Type 1 Diabetes Mellitus (T1DM) is an autoimmune disease that occurs due to destruction of the islets of Langerhans in the pancreas. These islets contain β cells and when destroyed, it reduces the body’s ability to produce insulin leading to hyperglycemia.

Agilent Technologies Inc. today announced its Ki-67 IHC MIB-1 pharmDxis now FDA approved as an aid in identifying patients with early breast cancer at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.

For many metastatic cancer patients, a one-time whole-genome analysis of a biopsy may be enough to identify their treatment options, a new study has found.

Today, WHO and HRP have launched a new guideline to help countries make faster progress, more equitably, on the screening and treatment of this devastating disease.

On July 6, 2021, Agilent Technologies (NYSE: A) announced a strategic collaboration with GenomiCare Biotechnology in a move aimed to advance the application of the latest Next Generation Sequencing (NGS) technology into the clinical and scientific arena.